Vaccine
Talk

The increasing population of immunocompromised individuals, particularly pediatric cancer patients and bone marrow transplants (BMTs) recipients, face an increased risk of vaccine-preventable diseases. Evolving dynamics in immunosuppression, propelled by cancer therapy advancements, underscore the necessity for tailored revaccination strategies.

Revaccinating pediatric oncology patients present challenges owing to compromised immune systems from cancer and treatments. Although revaccination is a vital intervention to address this immunity gap, its execution is complex, considering factors such as optimal timing, vaccine selection, compliance, and the patients' overall health status.

In Egypt, despite significant advancements in the survival of childhood cancer patients, their revaccination is frequently overlooked. This neglect stems from a substantial caseload, insufficient awareness among oncologists and parents, and the absence of a unified global or national vaccination schedule for this subgroup.

The consensus outlines standardized revaccination guidelines for childhood cancer survivors, developed by collaborating specialists in pediatric oncology, infectious diseases, and immunization.

Revaccination policy

• Administer vaccines six months post-treatment, beginning at 12 months for BMT patients without antibody level assessment.
• Children diagnosed after completing general vaccination need a booster shot.
• Those diagnosed before completion require a full re-vaccination schedule.
• BMT patients need a complete revaccination schedule.

In conclusion, revaccination is not only safe but also imperative. These guidelines serve as a crucial resource for healthcare professionals, offering a nuanced approach to revaccination within pediatric oncology.